Nitisinone (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nitisinone" in Italian language version.

refsWebsite

Global rank Italian rank

2^nd place

7^th place

4^th place

9^th place

799^th place

22^nd place

1^st place

3,537^th place

1,385^th place

doi.org

McKiernan PJ, Nitisinone in the treatment of hereditary tyrosinaemia type 1, in Drugs, vol. 66, n. 6, 2006, pp. 743–50, DOI:10.2165/00003495-200666060-00002, PMID 16706549.
Phornphutkul C, Introne WJ, Perry MB, Isa Bernardini, Mark D. Murphey, Diana L. Fitzpatrick, Paul D. Anderson, Marjan Huizing e Yair Anikster, Natural history of alkaptonuria, in New England Journal Medicine, vol. 347, n. 26, 2002, pp. 2111–21, DOI:10.1056/NEJMoa021736, PMID 12501223. URL consultato il 13 aprile 2012 (archiviato dall'url originale il 5 gennaio 2010).
Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL, From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug, in Journal of Inherited Metabolic Disease, vol. 42, n. 21, 1998, pp. 498–506, DOI:10.1023/A:1005458703363, PMID 9728330.
Kavana M, Moran GR, Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione, in Biochemistry, vol. 42, n. 34, 2003, pp. 10238–45, DOI:10.1021/bi034658b, PMID 12939152.

McKiernan PJ, Nitisinone in the treatment of hereditary tyrosinaemia type 1, in Drugs, vol. 66, n. 6, 2006, pp. 743–50, DOI:10.2165/00003495-200666060-00002, PMID 16706549.
Phornphutkul C, Introne WJ, Perry MB, Isa Bernardini, Mark D. Murphey, Diana L. Fitzpatrick, Paul D. Anderson, Marjan Huizing e Yair Anikster, Natural history of alkaptonuria, in New England Journal Medicine, vol. 347, n. 26, 2002, pp. 2111–21, DOI:10.1056/NEJMoa021736, PMID 12501223. URL consultato il 13 aprile 2012 (archiviato dall'url originale il 5 gennaio 2010).
Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL, From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug, in Journal of Inherited Metabolic Disease, vol. 42, n. 21, 1998, pp. 498–506, DOI:10.1023/A:1005458703363, PMID 9728330.
Kavana M, Moran GR, Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione, in Biochemistry, vol. 42, n. 34, 2003, pp. 10238–45, DOI:10.1021/bi034658b, PMID 12939152.

Phornphutkul C, Introne WJ, Perry MB, Isa Bernardini, Mark D. Murphey, Diana L. Fitzpatrick, Paul D. Anderson, Marjan Huizing e Yair Anikster, Natural history of alkaptonuria, in New England Journal Medicine, vol. 347, n. 26, 2002, pp. 2111–21, DOI:10.1056/NEJMoa021736, PMID 12501223. URL consultato il 13 aprile 2012 (archiviato dall'url originale il 5 gennaio 2010).